<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01343225</url>
  </required_header>
  <id_info>
    <org_study_id>IISP # 38879</org_study_id>
    <nct_id>NCT01343225</nct_id>
  </id_info>
  <brief_title>Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection</brief_title>
  <official_title>Pilot Study of the Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>East Carolina University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>East Carolina University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      2. Objectives

        1. To determine the vitamin D status of African-American HIV patients who are HIV-treatment
           na√Øve.

        2. To compare the effects of an efavirenz-containing regimen to a protease inhibitor
           regimen on 25-hydroxyvitamin D and 1,25 dihydroxyvitamin D3 levels.

        3. To compare the effect on bone density of a tenofovir- and efavirenz-containing regimen
           to a regimen that does not contain these drugs.

        4. To compare the efficacy of an alternative regimen (raltegravir, darunavir, ritonavir) to
           a standard once-daily regimen (tenofovir-emtricitabine-efavirenz).

      Hypothesis

      The investigators hypothesize that patients receiving efavirenz will be more likely to have
      lower 25-hydroxyvitamin D and 1,25 dihydroxyvitamin D3levels based on the fact that efavirenz
      is an inducer of CYP3A4 and CYP24 enzymes that degrade 25-hydroxyvitamin D and 1,25
      dihydroxyvitamin D3, respectively, to inactive metabolites. The investigators speculate that
      patients on a tenofovir-containing regimen will be more likely to have progression of bone
      density loss compared to those in the non-tenofovir-containing regimen.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vitamin D levels and bone density</measure>
    <time_frame>48 weeks</time_frame>
    <description>collection of vitamin d levels and bone density measured before and at end of 48 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>viral load and CD 4 count</measure>
    <time_frame>48 weeks</time_frame>
    <description>Viral load and CD 4 at baseline and 48 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>atripla</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>darunavir ritonavir raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>experimental</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atripla</intervention_name>
    <description>once a day</description>
    <arm_group_label>atripla</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darunavir ritonavir raltegravir</intervention_name>
    <description>as directed</description>
    <arm_group_label>darunavir ritonavir raltegravir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 18 and 50 years old

          -  HIV infection and HIV RNA &gt; 4000 copies/ml of plasma

        Exclusion Criteria:

          -  known risks for osteoporosis, including low body mass index (BMI &lt; 20)

          -  chronic alcohol use

          -  chronic steroid use

          -  use of phenytoin or phenobarbital

          -  chronic renal insufficiency (calculated glomerular filtration rate &lt; 50 ml/min)

          -  males with testosterone deficiency, and post-menopausal females will be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2011</study_first_submitted>
  <study_first_submitted_qc>April 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2011</study_first_posted>
  <last_update_submitted>April 27, 2011</last_update_submitted>
  <last_update_submitted_qc>April 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Paul Cook</name_title>
    <organization>East Carolina University</organization>
  </responsible_party>
  <keyword>African american vitamin d bone density</keyword>
  <keyword>African American male or female treatment naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

